

# Karen-Lise G Spindler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1811808/publications.pdf>

Version: 2024-02-01

49  
papers

1,520  
citations

430874

18  
h-index

315739

38  
g-index

50  
all docs

50  
docs citations

50  
times ranked

2554  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative Cell-Free DNA, <i>KRAS</i> , and <i>BRAF</i> Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan. <i>Clinical Cancer Research</i> , 2012, 18, 1177-1185.	7.0	244
2	Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0108247.	2.5	109
3	Reirradiation of locally recurrent rectal cancer: A systematic review. <i>Radiotherapy and Oncology</i> , 2014, 113, 151-157.	0.6	102
4	Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 2984-2991.	5.1	94
5	Can we save the rectum by watchful waiting or transanal microsurgery following (chemo) radiotherapy versus total mesorectal excision for early rectal cancer (STAR-TREC study)? protocol for a multicentre, randomised feasibility study. <i>BMI Open</i> , 2017, 7, e019474.	1.9	87
6	Systematic review: brain metastases from colorectal cancer—Incidence and patient characteristics. <i>BMC Cancer</i> , 2016, 16, 260.	2.6	82
7	Changes in mutational status during third-line treatment for metastatic colorectal cancer—Results of consecutive measurement of cell free DNA, <i>KRAS</i> and <i>BRAF</i> in the plasma. <i>International Journal of Cancer</i> , 2014, 135, 2215-2222.	5.1	76
8	Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2017, 22, 1049-1055.	3.7	73
9	The importance of <i>KRAS</i> mutations and <i>EGF61A&gt;G</i> polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2009, 20, 879-884.	1.2	72
10	Controls to validate plasma samples for cell free DNA quantification. <i>Clinica Chimica Acta</i> , 2015, 446, 141-146.	1.1	63
11	Measuring <i>KRAS</i> Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. <i>Translational Oncology</i> , 2018, 11, 1220-1224.	3.7	63
12	Phase II trial of temsirolimus alone and in combination with irinotecan for <i>KRAS</i> mutant metastatic colorectal cancer: Outcome and results of <i>KRAS</i> mutational analysis in plasma. <i>Acta Oncologica</i> , 2013, 52, 963-970.	1.8	56
13	Clinical utility of <i>KRAS</i> status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. <i>European Journal of Cancer</i> , 2015, 51, 2678-2685.	2.8	48
14	Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. <i>Clinica Chimica Acta</i> , 2015, 439, 97-101.	1.1	33
15	Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. <i>Acta Oncologica</i> , 2017, 56, 7-16.	1.8	33
16	Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 11542.	3.3	25
17	The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus. <i>Cancers</i> , 2021, 13, 2451.	3.7	25
18	Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization. <i>Radiotherapy and Oncology</i> , 2018, 128, 375-379.	0.6	21

#	ARTICLE	IF	CITATIONS
19	Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. <i>Tumor Biology</i> , 2017, 39, 101042831773097.	1.8	18
20	Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer. <i>Acta Oncol<sup>3</sup>gica</i> , 2020, 59, 1424-1429.	1.8	18
21	Colorectal cancer, comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort. <i>British Journal of Cancer</i> , 2016, 114, 96-102.	6.4	17
22	Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2022, 127, 500-513.	6.4	15
23	Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients—a phase II and translational research study. <i>Anticancer Research</i> , 2014, 34, 845-50.	1.1	14
24	Robust dose planning objectives for mesorectal radiotherapy of early stage rectal cancer – A multicentre dose planning study. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019, 11, 14-21.	1.9	12
25	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. <i>Tumor Biology</i> , 2018, 40, 101042831881120.	1.8	10
26	Mesorectal radiotherapy for early stage rectal cancer: A novel target volume. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 104-111.	1.7	10
27	Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with <i>RAS</i> -mutated or <i>BRAF</i> -mutated metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2021, 149, 1385-1397.	5.1	10
28	Cell-free DNA levels in colorectal cancer patients treated with irinotecan, healthy controls, and non-cancer patients with comorbidity. <i>Journal of Clinical Oncology</i> , 2014, 32, 3559-3559.	1.6	9
29	Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review. <i>Clinical and Translational Oncology</i> , 2019, 21, 874-880.	2.4	8
30	Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. <i>Acta Oncol<sup>3</sup>gica</i> , 2020, 59, 1016-1023.	1.8	8
31	A melt-electrowritten filter for capture and culture of circulating colon cancer cells. <i>Materials Today Bio</i> , 2020, 6, 100052.	5.5	8
32	TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. <i>Tumor Biology</i> , 2015, 36, 4301-4308.	1.8	7
33	A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer. <i>Cancers</i> , 2022, 14, 1697.	3.7	7
34	Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 279-287.	2.3	6
35	Measurement of circulating free DNA in squamous cell carcinoma of the anus and relation to risk factors and recurrence. <i>Radiotherapy and Oncology</i> , 2020, 150, 211-216.	0.6	6
36	Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Anorectal function and radiation dose to pelvic floor muscles after primary treatment for anal cancer. <i>Radiotherapy and Oncology</i> , 2021, 157, 141-146.	0.6	4
38	Pemetrexed and Gemcitabine for Chemotherapy Refractory Colorectal Cancer—Results of a Phase II and Translational Research Study. <i>Journal of Cancer Therapy</i> , 2013, 04, 44-50.	0.4	4
39	Management of late adverse effects after chemoradiation for anal cancer. <i>Acta Oncologica</i> , 2021, 60, 1688-1701.	1.8	4
40	A 3-weekly schedule of irinotecan and panitumumab for wild-type <i>KRAS</i> metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 135-145.	0.8	3
41	Intensified Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Anus—A Population-Based Experience from the Danish Anal Cancer Group. <i>Cancers</i> , 2021, 13, 3226.	3.7	3
42	Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study. <i>Cancer Medicine</i> , 2021, 10, 3224-3230.	2.8	2
43	Total cell-free DNA measurement in metastatic colorectal cancer with a fast and easy direct fluorescent assay. <i>Molecular and Clinical Oncology</i> , 2022, 16, 64.	1.0	2
44	Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases—a report from the Danish Anal Cancer Group. <i>Acta Oncologica</i> , 2022, 61, 321-327.	1.8	1
45	“Global Multidisciplinary Team Meetings” Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC). <i>Clinical Colorectal Cancer</i> , 2022, , .	2.3	1
46	Hypoxia and local tumour control in squamous cell carcinoma of the anus—a hypothesis-generating study. <i>Acta Oncologica</i> , 2022, 61, 1132-1135.	1.8	1
47	KRAS mutation status, comorbidity, and mortality in patients with metastatic colorectal cancer in Denmark. <i>Acta Oncologica</i> , 2018, 57, 1727-1729.	1.8	0
48	Contact therapy: A feasible option for local treatment of rectal cancer in non-operable patients—A Danish experience. <i>Journal of Clinical Oncology</i> , 2014, 32, e14543-e14543.	1.6	0
49	KRAS testing practice in Denmark between 2009 and 2013. <i>Journal of Clinical Oncology</i> , 2017, 35, 654-654.	1.6	0